Bispecifics Network

91% of Community Oncology Sites Offer Bispecifics Despite Barriers

Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.

Building Community Infrastructure for Bispecifics and CAR T

For Bhavana Bhatnagar, DO, delivering bispecifics and CAR T-cell therapy requires infrastructure, education, SOPs, and experienced academic colleagues.

Expanding Access to CAR T-Cell Therapy, Bispecific Antibodies: Swarup Kumar, MD

Swarup Kumar, MD, emphasizes that preparation is central to positive outcomes and includes patient education and early intervention when needed.

Advance Planning Eases Bispecific Therapy Burden for Patients

Community oncologists are steadily adopting bispecific antibodies for myeloma, but advance planning and tocilizumab remain key to safe access.

Before the First Bispecific Dose, Community Practices Need a Playbook

Designated teams, standardized SOPs, and scalable workflows are essential before a community practice's first bispecific dose.

Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently

Community oncology practices are building bispecific programs in diverse configurations to retain patients and scale safely.

Infrastructure, Payment Gaps Persist for Bispecifics in the Community

Community oncology practices face major infrastructure and reimbursement gaps when delivering bispecific antibodies.

Bispecifics in the Community: Infrastructure, Education, the Future